To determine the role of intestinal alkaline phosphatase (IAP) in enteral starvation-induced gut barrier dysfunction and to study its therapeutic effect as a supplement to prevent gut-derived sepsis. Background: Critically ill patients are at increased risk for systemic sepsis and, in some cases, multiorgan failure leading to death. Years ago, the gut was identified as a major source for this systemic sepsis syndrome. Previously, we have shown that IAP detoxifies bacterial toxins, prevents endotoxemia, and preserves intestinal microbiotal homeostasis. Methods: WT and IAP-KO mice were used to examine gut barrier function and tight junction protein levels during 48-hour starvation and fed states. Human ileal fluid samples were collected from 20 patients postileostomy and IAP levels were compared between fasted and fed states. To study the effect of IAP supplementation on starvation-induced gut barrier dysfunction, WT mice were fasted for 48 hours +/− IAP supplementation in the drinking water. Results: The loss of IAP expression is associated with decreased expression of intestinal junctional proteins and impaired barrier function. For the first time, we demonstrate that IAP expression is also decreased in humans who are deprived of enteral feeding. Finally, our data demonstrate that IAP supplementation reverses the gut barrier dysfunction and tight junction protein losses due to a lack of enteral feeding. Conclusions: IAP is a major regulator of gut mucosal permeability and is able to ameliorate starvation-induced gut barrier dysfunction. Enteral IAP supplementation may represent a novel approach to maintain bowel integrity in critically ill patients.
syndrome 1,2 and subsequently it has become clear that a key underlying problem relates to the lack of enteral nutrition (EN). Indeed, early enteral feeding, even in the form of minimal trophic feeds, has been shown to improve outcomes and has become a standard of care in critical care settings. [3] [4] [5] The mechanisms underlying the beneficial effects of enteral feeding are not well understood, but nutrient deprivation has been shown to disrupt the integrity of the intestinal epithelium, leading to the permeation of noxious molecules. 6, 7 Even within a short period of enteral fasting, functional and morphological changes have been reported, 6, 8, 9 including a disruption in the intestinal tight junctions (TJs), resulting in increased intestinal permeability 9, 10 and the passage of luminal proinflammatory molecules, toxins, and pathogens into the circulation. 7, 11 TJs are composed of transmembrane and cytosolic proteins, such as, claudins, occludin, and zona occludens. 12 The modification of TJ proteins and paracellular permeability is dynamically regulated by various stimuli and is closely associated with a broad spectrum of diseases. 13 Intestinal mucosal inflammation is associated with a decrease in TJ protein expression, loss of transepithelial electrical resistance, and an increase in the permeability to macromolecules such as inulin. 14 Miyasaka et al 15 showed that blockade of Myd88, a downstream signaling molecule of toll-like receptors (TLRs), prevents intestinal inflammation and barrier dysfunction seen in a mouse total parenteral nutrition (TPN) model.
The brush border enzyme intestinal alkaline phosphatase (IAP) is expressed in the small-intestinal epithelium 16 and has recently been identified as a key factor at the interface between the host and the gut microbiota. 17, 18 IAP has the ability to detoxify a variety of proinflammatory mediators that exist within the gut lumen, including adenosine triphosphate 19 and the TLR ligands: lipopolysaccharide (LPS), flagellin, and -cytosine-phosphate-guanine-(CpG) DNA. 20 We have previously shown that IAP knockout mice have an impaired ability to detoxify luminal LPS and seem to be more susceptible to gut-derived inflammatory conditions. 21, 22 Interestingly, IAP levels are known to decrease dramatically in the setting of starvation in rodents. 23, 24 Given the known function of IAP and the dependence on EN for its expression, we speculated that this enzyme might represent the key mediator through which enteral feeding maintains the gut barrier and protects critically ill patients from systemic sepsis and multiorgan failure.
In this study, we show that the loss of IAP expression is associated with decreased intestinal junction proteins and impaired barrier function. For the first time, we demonstrate that IAP expression is also decreased in humans who are deprived of enteral feeding, similar to the previous findings shown in rodents. Finally, we provide evidence that IAP supplementation could represent a novel therapy to maintain bowel integrity, protecting the host against the development of the systemic inflammatory state seen in some critically ill patients.
MATERIALS AND METHODS
For detailed information please see the online Supplemental Data File (Supplemental Digital Content, available at http://links .lww.com/SLA/A638, which details Materials and Methods section).
Human Subjects
Ileal fluid samples were collected from inpatients at the Massachusetts General Hospital (MGH). IAP levels from the first postoperative sample with enteric contents represented the fasted state and were compared with the last postoperative sample collected, representing the normal fed state. Demographics and clinical characteristics of patients were obtained from the medical records. All participants provided written informed consent, and the study was approved by the MGH institutional review board.
Animals
IAP-KO mice (Akp 3−/− , Mus musculus C57BL/6) construction has been described elsewhere. 25 
Starvation Model
WT mice (n = 5 per group), each weighing approximately 25 g, were used. Mice were housed with no chow diet for 48 hours to repress the expression of IAP as previously described. 24 Animals had free access to drinking water supplemented with IAP (calf intestinal alkaline phosphatase, Sigma Aldrich) 150 U/mL, IAP 300 U/mL, or an IAP vehicle (control group). After 48 hours without food, mice were euthanized and intestinal tissues collected for further analysis.
Intestinal Loop Model
Small intestinal loops were constructed in the proximal jejunum as previously described (See Data File, Supplemental Digital Content, available at http://links.lww.com/SLA/A638, for detailed Materials and Methods). 26
Intestinal Alkaline Phosphatase Essay
Human ileal fluid samples were homogenized in water (10 mg/mL), centrifuged (3000 rpm) and the supernatant collected to determine protein and IAP enzyme activity as previously described (See Data File, Supplemental Digital Content, available at http://links.lww.com/SLA/A638, for more details). 22
In vitro Cytokine Response to Luminal Contents
The luminal contents from the intestinal loops were centrifuged (15,000 rpm for 15 minutes at 4 • C); the supernatant was added to murine RAW 264.7 cells, and incubated overnight; TNF-α levels in the media were quantified by enzyme-linked immunosorbent assay (ELISA).
In vivo Intestinal Permeability
Mice were gavaged with a phosphate buffer saline (PBS, pH 7.2) containing fluorescein isothiocyanate (FITC)-dextran (4 or 10 kDa) at a dose of 300 mg/kg body weight to assess intestinal permeability as previously described (See Data File, Supplemental Digital Content, available at http://links.lww.com/SLA/A638, for more details). 22
Quantitative Real-Time PCR
The terminal ileum was isolated for RNA extraction and qRT-PCR (See Data File, Supplemental Digital Content, available at http://links.lww.com/SLA/A638, for more details). The average copy number of messenger RNA (mRNA) expression in control samples was set to 1.0.
Statistical Analysis
IAP levels in the fasting versus fed state were compared using the Wilcoxon signed-rank statistical test. In animal studies, statistical significance between 2 groups was tested using the 2-tailed Student t test. Statistical significance between more than 2 groups was tested using 1-way analysis of variance with Tukey's multiple-comparison post hoc tests. A P < 0.05 was considered statistically significant (See Data File, Supplemental Digital Content, available at http://links.lww .com/SLA/A638, for more details).
RESULTS

Endogenous IAP Plays an Important Role in the Gut Barrier Function
Disruption in gut barrier function results in translocation of luminal pathogens and toxins into the blood stream. We have showed earlier that IAP-KO mice are prone to endotoxemia and sepsis. 22, 24 To study the effect of endogenous IAP on gut barrier function, we compared the intestinal permeability in IAP-KO and WT mice. Eightweek-old male mice were orally gavaged with 300 mg/kg body weight FITC-labeled dextran (4000 MW) to assess the paracellular permeability. Ninety minutes later, FITC-dextran concentration in the serum was measured using a fluorospectrophotometer. We found that IAP-KO mice had a twofold increase in intestinal permeability to FITC-dextran 4-kDa compared to WT mice ( Fig. 1A) . To better assess the paracellular permeability to macromolecules, we measured the intestinal permeability to higher molecular weight FITC-dextran (10-kDa). The absence of endogenous IAP also resulted in significantly higher 10-kDa FITC-dextran in the serum of IAP-KO mice compared to WT ( Fig. 1B) .
To understand the mechanism by which IAP deletion increased intestinal permeability in mice, we assessed TJ protein expression in the intestinal tissue of IAP-KO compared to WT mice. Altering the abundance of junctional proteins claudin1 and occludin is known to increase intestinal paracellular permeability. 13, 27, 28 Furthermore, the depletion in ZO-1 protein levels has been shown to disrupt gut barrier function. 14 We found that the absence of IAP resulted in significant decreases in the expression of the junctional proteins claudin1, occludin, ZO-1, and ZO-2 in the intestinal tissue (Fig. 1C ). These results suggest that the endogenous IAP plays a crucial role in maintaining gut barrier function through regulation of junctional protein expression.
Reduction in Endogenous Anti-inflammatory Effects in the Jejunum of IAP-KO Mice
The aforementioned data indicate that the absence of IAP has a damaging effect on barrier function. In the gut, elevated levels of mucosal inflammatory cytokines such as TNF-α have been shown to induce intestinal permeability to macromolecules. 29, 30 Previous studies have shown that bacterial endotoxins induce mucosal inflammation and play a pivotal role in gut barrier dysfunction. 31 Given the known function of IAP as an anti-inflammatory factor, we studied the effect of endogenous IAP on bacterial proinflammatory mediators in a physiologic environment. We incubated bacterial toxins in an isolated jejunal loop of intestine in WT and IAP-KO mice. Two hours later, the luminal contents were collected, centrifuged to eliminate bacteria and food debris, the supernatant applied to mouse RAW 264.7 macrophage cells, and after an overnight incubation, TNF-α levels were assayed in the cell media. Lower level of endogenous IAP disrupts gut barrier function. WT and IAP-KO mice (n = 5) were orally gavaged with FITC-dextran to assess intestinal permeability. Ninety minutes later, mice were euthanized, blood was collected via heart puncture, and serum assayed for FITCdextran concentration. Serum levels of FITC-dextran of IAP-KO mice were compared with those of WT: A, Serum 4-kDa FITC-dextran (μg/mL). B, Serum 10-kDa FITCdextran (μg/mL). Upon euthanasia in the same mice groups (n = 5), terminal ileum was harvested to extract tissue RNA. Quantitative realtime polymerase chain reaction was performed to determine the levels of tight junction protein expression. C, Junctional protein mRNA expression in the terminal ileum of IAP-KO mice compared with WT. Values are expressed as mean ± SEM (standard error of mean). Statistical significance between 2 groups was tested using the 2-tailed Student t test; * P < 0.05, †P < 0.01.
FIGURE 2. Lower level of endogenous IAP in intestinal loops
results in higher inflammatory response of mice macrophages to bacterial proinflammatory mediators. Laparotomy was performed on IAP-KO and WT mice (n = 5 per group) under general anesthesia and a 5-cm jejunal loop was constructed. 100 μL of either endotoxin-free water, LPS (100 ng/mL), Flagellin (100 ng/mL), or CpG DNA (10 μg/mL) was instilled by injection into the loop. After 2 hours, although still under anesthesia, the loop was harvested, and the supernatants of the luminal contents were added to murine RAW 264.7 cells, incubated overnight, and TNF-α levels in the media quantified by ELISA. Values are expressed as mean ± SEM. Statistics: Statistical significance between 2 groups was tested using the 2-tailed Student's t test; †P < 0.01, ‡P < 0.001. contents from the intestinal loop of IAP-KO mice instilled with LPS caused more TNF-α release than their WT counterparts (P = 0.006). We observed the same effect in regard to 2 other bacterial inflammatory mediators, flagellin and CpG DNA (1117.9 ± 21.6 vs 662.0 ± 60.0 pg/mL cell media; P < 0.001) and (949.6 ± 57.3 vs 638.7 ± 61.8 pg/mL cell media; P = 0.006), respectively ( Fig. 2 ). These data demonstrate that the endogenous IAP enzyme functions as an anti-inflammatory factor, inhibiting the proinflammatory effects of a variety of bacterially derived mediators.
Lack of Enteral Feeding Disrupts Intestinal Barrier Function
To further elucidate the impact of the endogenous IAP enzyme on gut barrier function, we examined the effects of silencing IAP expression by starvation. We have previously demonstrated that starvation (water only diet for 48 hours) results in a dramatic decrease in endogenous IAP levels. 23, 24 Accordingly, we fasted mice on a wateronly diet for up to 48 hours and compared the impact on intestinal permeability and junctional protein expression compared to mice on a standard chow diet. As shown in Figure 3A , there was a threefold increase in paracellular permeability to 4-kDa FITC-dextran in starved compared to normally fed mice (P = 0.04). Furthermore, starvation resulted in significantly higher passage of larger molecular weight FITC-dextran 10-kDa (P = 0.01) ( Fig. 3B ).
We next quantified the mRNA levels of junctional proteins in the intestinal tissue of starved and fed mice. Our results showed that starvation significantly lowered the expression of occludin and ZO-3 ( Fig. 3C ).
FIGURE 3.
Starvation disrupts gut barrier function. Groups of mice (n = 5) were food starved for 48 hours with free access to drinking water. The control groups (n = 5) were housed with free access to regular chow diet and drinking water. Mice were orally gavaged with FITC-dextran to assess intestinal permeability. Ninety minutes later, mice were euthanized, blood was collected via heart puncture, and serum assayed for FITC-dextran concentration. Serum levels of FITCdextran of starved mice were compared with those of well-fed mice: A, Serum 4-kDa FITC-dextran (μg/mL). B, Serum 10-kDa FITCdextran (μg/mL). Upon euthanasia in the same mice groups (n = 5), terminal ileum was harvested to extract tissue RNA. Quantitative real-time polymerase chain reaction was performed to determine the levels of tight junction protein expression. C, Junctional protein mRNA expression in the terminal ileum of starved mice compared to well-fed mice. Values are expressed as mean ± SEM. Statistical significance between 2 groups was tested using the 2-tailed Student t test; * P < 0.05.
Luminal Fluid From Starved Mice Has Lower Anti-inflammatory Effect
Previous reports have shown elevated levels of TNF-α in the intestinal epithelia of fasted animals. 32 Furthermore, TPN administration in mice has been shown to result in increased TLR expression in the gut leading to hyper-response to bacterially derived ligands. 33 We employed the intestinal loop model to delineate the impact of suppression of endogenous IAP on luminal proinflammatory molecules during enteral starvation. In this study, mice were fasted for 48 hours and a jejunal loop instilled with 100 μL of LPS (100 ng/mL). Two hours later, the abdominal incision was reopened and the loop contents collected and applied to the RAW 264.7 cells. Figure 4 shows that the luminal contents of jejunal loops from starved animals instilled with LPS resulted in a significantly higher TNF-α response from macrophage cells when compared to the contents from fed mice (P = 0.01).
Perioperative Fasting Reduces IAP Levels in Human Ileal Fluid
Although IAP silencing has been demonstrated in both rats and mice in response to starvation, 23, 24 it is unknown whether a similar regulation occurs in humans. We therefore sought to study the effect of enteral nutrient deprivation on human IAP levels. We enrolled 20 patients who had undergone ileostomy creation and collected effluents under fasted and fed conditions. The first enteric contents seen from the ileostomy after surgery was taken to represent the fasted condition and these IAP levels were compared with the enteric fluid obtained when the patient was eating normally. The demographic and clinical characteristics of the patients are shown in Table 1 . We found that IAP was significantly reduced in the fasting compared with the fed ileal fluid samples (176.5 ± 32.2 vs 381.9 ± 42.2 pmole pNPP hydrolyzed/min/μg of protein; P = 0.001) ( Fig. 5 ). Age, body mass index, ASA (American Society of Anesthesiologists) physical status, sex, type of diagnosis, history of diabetes, and history of hypercholesterolemia had no effect on the levels of IAP.
Oral Supplementation With IAP Upregulates Junctional Protein Expression
On the basis of our previous results, we sought to study the effect of exogenous IAP on the TJ protein levels. WT mice were given free access to normal chow diet and drinking water. In one of the groups (n = 5), IAP was added to drinking water at a concentration of 300 U/mL. The water was changed daily with new addition of IAP. After 10 days of treatment, the mice were euthanized and the terminal ilea were collected for RNA extraction. Figure 6 shows that oral supplementation with IAP increased the expression of claudin1 and the cytosolic junctional proteins ZO-1 and ZO-3 (6.9 and 10.3 mRNA relative expression, respectively; P = 0.03 and P = 0.02, respectively).
FIGURE 4.
Starvation diminishes the endogenous antiinflammatory factors in the gut. Groups of mice (n = 5) were fed or food starved for 48 hours with free access to drinking water, followed by construction of the loop in the proximal jejunum. 100 μL of either endotoxin-free water or LPS (100 ng/mL) was instilled into the loops using a 28-gauge needle. After 2 hours, although still under anesthesia, the loop was harvested, and the supernatants of the luminal contents were added to murine RAW 264.7 cells, incubated overnight, and TNF-α levels in the media quantified by ELISA. Values are expressed as mean ± SEM. Statistical significance between 2 groups was tested using the 2-tailed Student t test; * P < 0.05. 
Oral Supplementation With IAP Prevents Enteral Starvation-Induced Gut Barrier Dysfunction and Junctional Protein Losses in Mice
Inflammatory pathways are known to exert a major impact on gut barrier dysfunction related to fasting. 34, 35 Furthermore, we have shown the beneficial effect of exogenous IAP in the context of a variety of gut-derived inflammatory conditions. 22 We therefore sought to determine the effect of exogenous IAP supplementation on gut barrier function under conditions of starvation. In this study, WT mice were placed on a water-only diet ± different concentrations of IAP (150 U/mL and 300 U/mL). After 48 hours of food deprivation, mice were orally gavaged with FITC-dextran and 90 minutes later the animals were euthanized and blood and intestinal tissues were collected. Figure 7A shows that oral supplementation with 300 U/mL IAP reversed the effect of starvation on intestinal permeation of 4-kDa FITC-dextran (P = 0.04). In regard to serum levels of the higher molecular weight FITC-dextran 10-kDa, both doses of IAP (150 U/mL and 300 U/mL) significantly reduced the permeability to this macromolecule [(0.16 ± 0.03 vs 0.41 ± 0.08 10-kDa FITCdextran μg/mL; P = 0.036) and (0.16 ± 0.01 vs 0.41 ± 0.08 10-kDa FITC-dextran μg/mL; P = 0.032) ( Fig. 7B) ]. To further elucidate the therapeutic effect of IAP on starvation-induced barrier dysfunction, we quantified the expression of junctional proteins in the intestine from the starved mice ± IAP treatments. Figure 7C shows that oral treatment with 300 U/mL IAP in the drinking water significantly increased the levels of the tight junction gene products, claudin1, occludin, ZO-1, ZO-2, and ZO-3.
DISCUSSION
The lack of enteral feeding in critically ill patients has been linked to an increased risk of systemic sepsis and multiorgan failure. [2] [3] [4] Administration of parenteral nutrition in ICU patients is associated with increased intestinal permeability and endotoxemia, 7 whereas enteral feeding has been clearly demonstrated to improve outcomes in patients suffering from severe trauma. 5 It is thought that nutrient deprivation in the gut leads to a disruption in intestinal mucosal integrity through a reduction in tight junction protein expression. 36 An impaired gut mucosal barrier results in the systemic absorption of luminal inflammatory mediators, and perhaps other bacterially derived toxins. Interestingly, the precise mechanisms responsible for the beneficial effects of EN remain largely unknown.
The gut mucosal barrier is a complex system comprising a mucus layer and other luminal components, the epithelium, the tight junctions between the epithelial cells, and the immune system. 12, 13 The 2 major pathways by which luminal molecules cross the barrier are the transcellular and paracellular routes. A key component of the gut mucosal barrier is composed of the paracellular pathway, FIGURE 6. Exogenous IAP supplementation improves tight junction protein abundance. WT mice (n = 5) were housed in MGH animal facility with free access to normal chew diet and drinking water. In one of the groups (n = 5), IAP was added to drinking water at a concentration of 300 U/mL. After 10 days of treatment, the mice were euthanized and intestinal tissues were collected for RNA extraction. Values are expressed as mean ± SEM. Statistical significance between IAP treated and no treatment groups was tested using the 2-tailed Student t test; * P < 0.05.
which is considered to be the major route for diffusion of hydrophilic molecules across the intestinal epithelia. This pathway is regulated by tight junctions that require the assembly of several proteins with linkage to the actin-based cytoskeleton, including occludin, the claudins, junction adhesion molecule, and the zonula occludens. [12] [13] [14] IAP is a brush-border enzyme that is exclusively produced by the enterocytes of the proximal small intestine. 16 This enzyme is secreted into the intestinal lumen, especially in response to luminal fats and other nutrients. 37 IAP has a myriad of functions that include detoxification of LPS and other bacterial products, 20 dephosphorylation of adenosine triphosphate, 19 prevention of gut inflammation, and preservation of intestinal microbiotal homeostasis. 18 The pharmacological properties of exogenous IAP include the prevention of sepsis, 35 inflammatory bowel disease, 21 and the metabolic syndrome. 22 On the basis of the known functions of IAP and the fact that its expression is lost with starvation in rodents, 23, 24 we sought to explore a potential role for this enzyme in the gut barrier dysfunction that is associated with the lack of EN. Our findings suggest that the endogenous IAP enzyme plays a major role in maintaining intestinal barrier function, likely thorough its ability to block a variety of inflammatory pathways and through its regulation of the expression of tight junction proteins. A strong link exists between starvation, mucosal inflammation, and intestinal barrier dysfunction. Inflammatory cytokines such as TNF-α and IL-1β are associated with downregulation of the junctional proteins, occludin and ZO-1, 14 and deletion of TLRs or the inhibition of their downstream signaling in the intestinal epithelium has been shown to prevent inflammation and improve intestinal barrier function in many mouse disease models. 38 Furthermore, a lack of enteral feeding increases intestinal inflammation and results in an increased sensitivity to luminal proinflammatory mediators. 32, 33 Miyasaka et al 15 showed that the blockade of Myd88, a downstream signaling molecule of TLRs, prevents intestinal inflammation and barrier dysfunction seen in a mouse TPN model. Similarly, inhibition of TNF-α signaling was shown to ameliorate the impairment in intestinal permeability due to enteral starvation. 29, 34 Because IAP blocks the inflammatory effects of a number of mediators, including the TLR ligands LPS, flagellin, and CpG DNA, 20 it is possible that the improvement in gut barrier function induced by this enzyme is related to its inhibition of inflammatory pathways in the gut. The increase in tight junction protein expression could be a direct effect of the IAP enzyme on these gene products, or an indirect effect through blockade of 1 or more inflammatory pathways. Further work will be needed to delineate the precise mechanism by which IAP maintains the intestinal tight junction barrier.
Our data are consistent with other reports linking starvation to gut barrier dysfunction. We demonstrated that starved animals are more sensitive to luminal proinflammatory mediators, based on the effects of the enteric contents on target cells in vitro. The changes seen with starvation compared to the fed state were similar to what we saw in the IAP-KO mice. Taken together, our data suggest that the decline in endogenous IAP due to enteral starvation plays a critical role in the development of barrier dysfunction and increased paracellular permeability. Further studies will be needed to more fully understand the impact of IAP deficiency in regard to gut mucosal dysfunction.
Although the focus of this study is on the acute barrier dysfunction that accompanies starvation and critical illness, it is thought that a more chronic impairment in the gut barrier (leaky gut) may lead to a variety of human diseases, including obesity, rheumatoid arthritis, asthma, and others. Indeed, we have recently reported on the beneficial effects of oral IAP in preventing the metabolic syndrome in mice. 22 Further studies will be needed to determine the precise role that the gut and perhaps IAP play in these chronic systemic inflammatory conditions.
In this study, we demonstrate for the first time that IAP expression is decreased in humans who are deprived of enteral feeding, similar to what has previously been shown in rodents. 23, 24 Given this apparent nutrient regulation of human IAP expression, we speculate that critically ill patients who are not being enterally fed will experience a decline in endogenous IAP activity and that this will predispose them to gut barrier dysfunction. It is interesting to note that decades ago the gut was identified as a major source for the systemic sepsis syndrome seen in some critically ill patients. Although the underlying cause of the gut dysfunction has remained a mystery, it has become clear that aggressive EN is of great benefit. Indeed, early enteral feeding, even in the form of minimal trophic feeds, has been shown to improve outcomes and has become a standard of care in critical care settings. [3] [4] [5] Given the functions of the endogenous IAP enzyme in regard to the preservation of gut mucosal integrity and the fact the levels of this enzyme are low in starved humans suggested us that IAP could be used in a therapeutic paradigm in clinical settings where EN may not be feasible. We therefore tested this idea FIGURE 8. Gut homeostasis during EN. The brush border enzyme IAP seems to play a crucial role in regulating the gut barrier function through a mechanism that involves the dephosphorylation of bacterial proinflammatory mediators in the intestinal lumen. By dephosphorylating bacterial toxins, IAP blocks their binding to TLR receptors, preventing inflammation in the gut. Inflammatory cytokines exert an inhibitory effect on the expression of tight junction proteins, resulting in disrupted gut barrier function. Lack of enteral feeding diminishes IAP levels in the intestine, resulting in hypersensitivity to bacterial toxins and elevated levels of inflammatory cytokines. Depletion of IAP leads to increased intestinal permeability.
in starved mice, providing supplemental IAP in their drinking water. Indeed, our results suggest that oral supplementation with IAP improves gut barrier function. IAP treatment upregulated TJ protein mRNA levels under normal fed conditions, but more importantly, when the animals were starved. IAP also improved gut barrier function as determined by macromolecular permeability. It is likely that IAP ameliorates the effects of enteral starvation on intestinal permeability by preventing the decline in junctional protein expression, although other mechanisms may also be at play, that is, detoxification of proinflammatory mediators in the intestinal lumen and prevention of gut wall inflammation (Fig. 8 ). IAP is a naturally occurring gut enzyme and has been safely administered to some patients without any adverse effects. 39 We therefore suggest that IAP may represent a novel clinical intervention to improve outcomes in the setting of critical illness.
DISCUSSANTS A. Harken (Oakland, CA):
The authors examine the traditional concept of lack of EN as causing intestinal barrier dysfunction, or, as Basil Pruitt and Doug Wilmore said many decades ago, the gut is the motor of multiple organ failure. I'm reminded of that statement of an elementary school science teacher of mine who told me that the inside of my intestines was actually outside of my body, and I never really believed that. But it reminds me then of Ed Deitch's observations back, again, decades ago, in which he took traumatic patients and demonstrated bacteria in their blood and assumed that somehow this was being translocated from the gut, and then Dr Gene Moore followed up on this.
So, in New Jersey, if you are hit hard, you get a bacterial translocation. But Gene actually cannulated the umbilical vein and ran a catheter down into the portal vein and collected 200 blood samples in patients who had actually become hypotensive, and was only able to get 6 of 200 positive blood cultures. All 6 were Staphylococcus epidermitis, which we assumed were contaminants. Therefore, at least in Denver, there was no bacterial translocation.
Ed then did some beautiful rodent studies in which multiple permutations with carbohydrate and lipid and proteins and then multiple elemental proteins all sustained gut barrier function. In fact, he even took little micro steel wool. I don't know how he got the rats to eat this stuff. Even just the mechanical stimulation seemed to sustain gut barrier function.
So my questions are 3. Is the gut really the motor of multiple organ failure? You did look at the 20 patients, which did seem to verify your hypothesis, but can we take data from rodents and extrapolate to people? Ultimately, when the gut barrier breaks down, what are the bacteria or toxins that are translocated? And then how did you select alkaline phosphatase? As we all know, there are lots of different phosphatases, and alkaline phosphatases are just phosphatases that happen more happily to metabolize a sugar in an alkaline environment. But there are acid phosphatases and there are lots of kinases and there are lots of other enzymes. If you induce any of those other enzymes, will they work just as well?
Response From S.R. Hamarneh:
Regarding translating the experiments from rodents to human, this remains an important and open question. The data for the 20 patients suggest that IAP levels will indeed be lower in the critically ill patient. But, whether IAP supplementation will be clinically helpful in that setting will need to be answered in the future with a proper clinical trial. Given all that we know about the biology of IAP, we are optimistic that this enzyme will be helpful in the clinical setting of critical illness.
Regarding the question of which ligands translocate into the blood, most of the emphasis has been on LPS. But, clearly other bacterial products and toxins such as CpG DNA and flagellin seem to play important roles in systemic inflammatory conditions. We believe that there are probably a wide range of bacterially derived mediators that come from the gut and systemically impact the host.
Regarding our choice of studying IAP, our laboratory has devoted many years to this particular enzyme because of its unique properties. It is produced exclusively in the intestine and secreted into the lumen where it maintains its functional capacity as it travels through the small and large intestines. IAP functions as a robust antiinflammatory factor, blocking LPS and many other bacterial products. We are not aware of any other gut phosphatase that has these functions.
DISCUSSANTS T. Buchman (Atlanta, GA):
One of the problems with oral administration of any polypeptide is it has to get past the stomach and pancreatic enzymes. My questions are as follows: Are you sure that the phosphatase made it down? And if you are sure, did you have to use a protease inhibitor to get it there?
The reason I ask is that there are data from Chang and others over the past several years suggesting that improvement in outcomes of serious gut ischemia reperfusion, multiple organ failure can be halved by introducing protease inhibitors orally in patients and experimental animals.
So, was there a vehicle and is there a potential that there was a vehicle effect? Did the IAP make it down and is there a potential strategy here to inhibit protease activity?
Response From S.R. Hamarneh:
Actually, IAP is a very hearty enzyme that is able to largely survive the acidity of the stomach. We measured IAP in stool in mice after oral supplementation and found an approximate 10-fold increase, confirming that the enzyme maintains its function throughout its trip down the gastrointestinal tract. IAP has also been studied as a treatment in patients with ulcerative colitis and in that study it was given intraduodenally and was associated with a marked improvement in the colitis in those patients. The addition of a protease is certainly something to consider, but based on our animal studies with IAP in the drinking water, an added protease may not be needed.
Response From R.A. Hodin:
As Sulaiman said, we think about 80% of the IAP survives the stomach acid. It's not so easy to figure that out, but it certainly does not get all degraded, and it survives in the lumen. We can even measure in the stool. We haven't tried something like protease inhibition, but theoretically this could enhance the amount of IAP delivered.
DISCUSSANTS
C.M. Schmidt (Indianapolis, IN):
I was curious as to whether you measured serum as well as luminal levels of alkaline phosphatase. Fractionation of serum alkaline phosphatase could identify an intestine-specific isoform of alkaline phosphatase. Serum intestinal alkaline phosphatase isoform levels might have potential as a prognostic marker for sepsis susceptibility. This might facilitate decision making regarding nutritional support perioperatively. Patients more susceptible to sepsis could be prospectively identified and undergo more proactive measures to ensure nutritional repletion to maintain optimal gut integrity.
Response From S.R. Hamarneh:
Regarding the serum level of alkaline phosphatases, in human blood only about 4% is from IAP, the remainder is composed of other alkaline phosphatase enzyme from tissues such as the liver and bone. IAP is secreted bidirectionally and the majority goes into the lumen.
We have not measured the level of IAP in patients' blood samples, but this is a good idea and something we would like to do in the future.
DISCUSSANTS J. Matthews (Chicago, IL):
I have no conflicts. My understanding had been that starvation reduces intestinal alkaline phosphatase through effects on enterocyte differentiation. You show that barrier function can be restored by enteral supplementation of intestinal alkaline phosphatase. What's the impact on enterocyte differentiation? Or is it purely a luminal effect that has secondary impact on blood levels of cytokines and that sort of thing? Is there a direct effect back on the enterocyte in terms of its state of differentiation by supplemental alkaline phosphatase?
Response From R.A. Hodin:
The loss of IAP is associated mostly with the atrophy that occurs with starvation. Essentially, if you can prevent the atrophy, whether through feeding, of course, or some other growth factors to the gut, you can largely maintain or restore IAP. In terms of the effect of the supplementation on enterocyte differentiation, we are not sure. We haven't really studied much in terms of whether the enzyme is directly affecting the enterocyte, except in regard to the junctional protein expression. That is probably a secondary effect, an indirect effect through inhibition of inflammatory pathways. Certainly, we are interested in pursuing whether IAP affects the phenotype of the cells themselves. That will have to be for future work.
DISCUSSANTS
M.G. SARR (Rochester, MN):
I have 3 specific questions. The first is, I missed it. Did you measure activity of alkaline phosphatase or did you measure protein in the lumen? Is there an inhibitor that might be involved in this, or is it actually a decrease in the quantitative amount of enzymes secreted? That's my first question.
Second, do you have a specific inhibitor of this that you could give an animal to see if it's the activity or some other thing?
The third question, your control group was a fasted mouse for 48 hours. Now, we know with some of the enhanced recovery after surgery data, that giving nutrients immediately up front, or maintaining them during the period of starvation, may have an effect on enterocyte function. So, do you have a control group of mice that have been starved but still are given nutrients parentally so that their nutritional status is similar?
Response From R.A. Hodin:
We have measured IAP every way, from mRNA to protein to activity of the enzyme. Most of the data we presented today is on the actual activity of the enzyme, which is decreased. But it all follows from mRNA to protein levels to the enzyme itself.
In terms of an inhibitor, there are inhibitors of IAP, and we have used them in some other work. Specifically phenylalanine is the most commonly used inhibitor for IAP. We have not done the inhibitor experiments in terms of this model, but in other studies we have used phenylalanine and have shown that by inhibiting endogenous IAP with phenylalanine, the anti-inflammatory effects are blocked.
Finally, you mentioned giving nutrients in other ways, perhaps through TPN. We have actually just started a collaboration with Dr Dan Teitelbaum at Michigan, who has a mouse model of prolonged TPN. It's a great model we are interested in and are just really beginning those studies. But, we have already seen that IAP levels are decreased with long-term TPN, so the lack of the enteral nutrients is key in terms of regulating IAP activity.
